Category - Markets

Maxim Group raised its price target for Abeona Therapeutics (NASDAQ:ABEO) to $35 from $17, citing advances in the gene therapy space and comparatives to competitor, AveXis. “Given the valuation gap between these two...

Maxim Group upgraded Celsion (NASDAQ:CLSN) to “buy” from “hold” with a $7 price target after the company renegotiate outstanding warrants, raising $15.6-million. Shares of Celsion were quoted at $4.96, down $1.09, or...

H.C. Wainwright initiated coverage of Myomo (NYSE MKT:MYO) with a “buy” rating and $12 price target. The stock closed at $6 on Sept. 29. Myomo is a wearable robotics company targeting a largely unmet need in providing a...

William Blair upgraded Zogenix (NASAQ:ZGNX) to “outperform” and Stifel more than doubled its price target to $55 from $26 after the company unveiled strongly positive Phase 3 data for ZX008 (fenfluramine) in Dravet...

Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced...

Paradigm Capital launched coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with a “buy” rating and price target of $2.25. The stock closed at 95 cents on Sept. 27. Profound is commercializing the TULSA-PRO medical...

BTIG initiated coverage of Oxford Immunotec Global (NASDAQ:OXFD) with a “buy” rating and $21 price target. The stock closed at $16.76 on Sept. 27. Oxford already has a successful product – TSPOT.TB test, which is...

Roth Capital Partners reinitiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $40 price target. The stock closed at $9.24 on Sept. 26. Savara is developing inhalable formulations of therapeutics with proven...

H.C. Wainwright raised its price target for Fibrocell Science (NASDAQ:FCSC) to $7.60 from $5.70 after the company announced first efficacy data from a single injection of FCX-007 in patients with recessive dystrophic...

H.C. Wainwright initiated coverage of Corium International (NASDAQ:CORI) with a “buy” rating and $15 price target. The stock closed at $10.88 on Sept. 25. Corium is a pure-play transdermal (TD) patch dug delivery...